Search
Myriad Genetics Inc
MYGNAdd to Watchlist
5.990USD
-0.010-0.17%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
565.46MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.17%
5 Days
+1.87%
1 Month
+27.72%
6 Months
-2.44%
Year to Date
-2.60%
1 Year
+6.96%
Key Figures
6.050Open
6.120High
1.32MVolume
LossP/E TTM
40.24P/E Dynamic
--Dividend TTM
1.40%Turnover Ratio
6.000Prev. Close
5.920Low
5.73MTurnover
LossP/E Static
1.68P/B
0.00%Div Yield TTM
-47.61%ROA
8.59052wk High
0.95Volume Ratio
-127.30MNet Profit
94.40MShares
-4.3142EPS TTM
1.77Beta
-76.73%ROE
3.53052wk Low
3.33%Amplitude
68.66%Gross Margin
565.46MMarket Cap
7.15Reward/Risk
3.91%Risk Rate
TradingKey Stock Score of Myriad Genetics Inc
Currency: USD Updated: 2026-07-02Key Insights
Myriad Genetics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 85 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Myriad Genetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Myriad Genetics Inc Highlights
StrengthsRisks
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 824.50M.
Overvalued
The company’s latest PE is -1.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 102.95M shares, decreasing 6.61% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 6.20M shares of this stock.
Analyst Rating
Based on
10
analysts
Hold
Current Rating
6.500
Target Price
+8.33%
Upside Space
Myriad Genetics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Myriad Genetics Inc Info
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Ticker SymbolMYGN
CompanyMyriad Genetics Inc
CEORaha (Samraat S)
Websitehttps://myriad.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Myriad Genetics Inc (MYGN)?
The current price of Myriad Genetics Inc (MYGN) is 5.99.
What is the symbol of Myriad Genetics Inc?
The ticker symbol of Myriad Genetics Inc is MYGN.
What is the 52-week high of Myriad Genetics Inc?
The 52-week high of Myriad Genetics Inc is 8.59.
What is the 52-week low of Myriad Genetics Inc?
The 52-week low of Myriad Genetics Inc is 3.53.
What is the market capitalization of Myriad Genetics Inc?
The market capitalization of Myriad Genetics Inc is 565.46M.
Is Myriad Genetics Inc (MYGN) currently rated as Buy, Hold, or Sell?
According to analysts, Myriad Genetics Inc (MYGN) has an overall rating of signal_hold, with a price target of 6.50.
What is the Earnings Per Share (EPS TTM) of Myriad Genetics Inc (MYGN)?
The Earnings Per Share (EPS TTM) of Myriad Genetics Inc (MYGN) is -3.95.